Skip to content

Open-label, randomized, two-treatment, two-period, two-sequence, cross-over, single dose, bioequivalence study comparing ISOPRINOSINE® FORTE 100 mg/mL Syrup to ISOPRINOSINE® 500 mg tablets in healthy male and female subjects under fasting conditions.

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-514146-37-00
Acronym
EWO-ISO-2024/BE2
Enrollment
36
Registered
2024-09-06
Start date
2024-10-24
Completion date
2024-11-21
Last updated
2024-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

not applicable (submitted trial is a bioequivalence study)

Interventions

None listed

Sponsors

Ewopharma AG
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Countries

Czechia

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026